Indoco Remedies Q1 FY27 Results (NSE: INDOCO)

· Analysis by Alpha Inflection

Signal: Loss reversed

The read

Q1FY27 headline profit is entirely an accounting gain from the slump sale of the ophthalmic division (₹9,734 lakh exceptional). Core business remains deep in the red: consolidated PBT before exceptional is -₹1,962 lakh, though this has improved from -₹3,666 lakh a year ago on cost cutting. Standalone EBITDA margin improved to 10.3% from 3.8% a year ago, but consolidated operating losses continue. The structural turnaround thesis hinges on whether domestic formulation growth (+12.2% YoY) and cost discipline can drive core profitability without reliance on asset sales.

Indoco Remedies Q1 FY27 key financials
MetricValueYoYQoQ
Revenue₹466.22 Cr8.2%-2.0%
EBIT₹-19.62 CrN/A
Net profit₹65.44 Cr280.0%
EPS₹7.09N/A
EBIT margin-4.2%

P&L walk

Revenue +8.2% YoY, but core operating profit (before exceptional) improved only marginally from -₹3,666 lakh loss to -₹1,962 lakh loss; reported profit entirely from one-off gain of ₹9,734 lakh on slump sale of ophthalmic division.

Segments

Only one primary segment (Pharmaceuticals) reported; geography shows India revenue +12.2% YoY (₹31,177 lakh vs ₹27,783 lakh) driving consolidated growth, while international revenue flat (₹15,445 lakh vs ₹15,303 lakh). No segment profit split disclosed.

Key positives

Key concerns

View original filing

Research and educational content only. Not investment advice.